Cellular energy metabolism
NAD+ is fundamental to the reactions cells use to transfer energy from nutrients into usable cellular energy.
Explore the research →CELLULAR ENERGY & NAD BIOLOGY
NAD+
Found naturally in every cell, NAD+ helps the body turn nutrients into usable energy and has become a major focus of metabolism and healthy-ageing research.
Cellular energyRedox biologyMetabolic health
Developing human evidenceHuman studies exist across direct NAD+ administration and the wider NAD-boosting field, but evidence differs substantially by intervention, route and clinical setting.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in NAD+?
NAD+ sits at the centre of the way cells produce energy and carry out essential maintenance. That is why it attracts so much interest around fatigue, metabolism, recovery and healthy ageing: the underlying idea is not simply 'more energy', but supporting processes the body relies on every day.
Metabolic health
NAD biology is closely linked with glucose handling, mitochondrial function and broader metabolic pathways.
Explore the research →Fatigue & recovery interest
Energy, fatigue and recovery are among the most common reasons people discuss NAD+ in wellness settings.
Explore the research →Cell maintenance & signalling
NAD+ also supports enzymes involved in cellular signalling, stress responses and maintenance processes.
Explore the research →THE SCIENCE BIT
The cell's reusable electron carrier.
NAD+ helps enzymes pass electrons during reactions that turn nutrients into usable energy. When it accepts electrons, it becomes NADH; the two forms work as a reusable pair.
NAD+ is also used by enzymes involved in DNA repair and cell regulation. That essential biology explains the interest, while the benefits of a particular supplement or infusion need their own human evidence.
See the studies & trials →- NAD+ / NADH
- The electron-carrying pair
- Sirtuins
- NAD-dependent cell regulation
- PARPs
- NAD use in DNA-repair responses
How this connects to the research
An established cellular role; administered-product outcomes depend on route and study.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where NAD+ connects with the body
These are the tissues and biological systems behind the interest in NAD+.
- Mitochondria
- Energy-producing reactions.
- Cell nucleus
- DNA repair and enzyme activity.
- Many tissues
- NAD chemistry is used throughout the body.
The research behind the interest
Cellular energy metabolism
NAD+ is fundamental to the reactions cells use to transfer energy from nutrients into usable cellular energy.
Human and mechanistic research supports NAD+'s central biochemical role, while clinical benefits from raising or administering NAD+ depend on the intervention and population studied.
Established biology · developing clinical evidenceExplore the studies →Metabolic health
NAD biology is closely linked with glucose handling, mitochondrial function and broader metabolic pathways.
Clinical research across the NAD family has explored metabolic outcomes, but results from NR, NMN, NADH and direct NAD+ cannot be treated as interchangeable.
Developing human evidenceExplore the studies →Fatigue & recovery interest
Energy, fatigue and recovery are among the most common reasons people discuss NAD+ in wellness settings.
Direct clinical evidence for broad fatigue or recovery benefits remains limited and subjective reports are mixed, including reports of both increased and reduced energy.
Limited direct evidenceExplore the studies →Cell maintenance & signalling
NAD+ also supports enzymes involved in cellular signalling, stress responses and maintenance processes.
These pathways provide a strong mechanistic rationale for research, but pathway activity should not be presented as proof of a specific clinical benefit.
Strong mechanistic rationaleExplore the studies →Healthy-ageing research
Age-related changes in NAD metabolism have made the NAD system a major area of ageing research.
Human studies of NAD-boosting strategies show biochemical target engagement more consistently than they show broad improvements in healthspan or function.
Active human researchExplore the studies →Disease-specific clinical research
NAD-related interventions are also being studied in defined clinical populations rather than only in general wellness settings.
Published human work includes disease-specific and pharmacokinetic studies, reinforcing that outcomes depend heavily on route, dose, formulation and population.
Indication-specific human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableNAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence ↗
113 eligible studies: 33 human intervention studies and 80 rodent studies
Oral and parenteral NAD-related interventionsVariedStudies from 2010 to October 2025
Oral NR and NMN consistently showed biochemical target engagement in humans, while functional and healthspan-relevant outcomes were heterogeneous.
No eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications.
Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review ↗
Randomized clinical trials of NAD+ and NADH supplementation
VariedVariedVaried
Systematic review examining safety and effectiveness of NAD+ and NADH supplementation across clinical conditions.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceDeveloping
3/5 evidence depth
Human intervention literature exists across NAD-related compounds, but direct NAD+ intervention evidence is much thinner than the broader NR/NMN literature.
✓
Clinical efficacyLimited
2/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceDeveloping
3/5 evidence depth
Short-term human data exist for related NAD-boosting approaches; parenteral NAD+ has much less outcomes evidence and sterile-compounding quality is a separate safety issue.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Rodent studies are numerous and frequently report metabolic, mitochondrial and inflammatory effects, but they remain preclinical.
HOW TO READ THESE SCORESStrong preclinical evidence · developing human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
NAD+ research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Cellular energy
RESEARCH AREA 02Redox biology
RESEARCH AREA 03Metabolic health
RESEARCH AREA 04Healthy-ageing research
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
Evidence attribution matters
NAD+The NAD+ evidence family
NR, NMN, NAD+ and NADH are biologically related, but evidence for one should not automatically be attributed to another.
NRprecursor
→conversion pathway
NAD+cellular coenzyme
↔redox pair
NADHreduced form
NMNprecursor
↗conversion pathway
Evidence attribution rule
Evidence belongs to the intervention actually studied. NR, NMN, NADH and administered NAD+ are related, but results cannot be silently transferred between them.
NR
DevelopingOral human intervention literature includes biochemical target engagement; functional outcomes remain heterogeneous.
NMN
DevelopingOral human trials report target engagement, with mixed or endpoint-specific clinical findings.
Open NMN profile →NAD+
Limited for direct wellness administrationDirect parenteral NAD+ has far less eligible outcomes evidence than the broader precursor literature.
NADH
Limited / indication-specificSome human trials exist, but NADH is a distinct intervention and should not be treated as direct NAD+ evidence.
Systematic-review snapshot
eligible studies
The review covered the wider NAD-boosting field. Oral NR/NMN had clearer biochemical target engagement than direct IV/IM NAD+ had eligible clinical outcomes evidence.
2026 systematic review · PMID 41655607 ↗10 randomized studies · 489 participants
This review included NAD-related interventions across several clinical conditions, including NADH and precursor-related approaches; it does not make all NAD-family interventions interchangeable.
Systematic review · PMID 37971292 ↗Direct IV NAD+ has a separate product-quality risk
FDA has warned that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial/endotoxin contamination risk. FDA has received adverse-event reports after injectable NAD+ use consistent with excessive endotoxins.
2026 example A January 2026 FDA warning letter described an NAD+ compounded lot with excessive bacterial endotoxins after three patients developed symptoms and were directed to emergency care.
FDA sterile-compounding reminder ↗FDA warning letter · Jan 2026 ↗What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with NAD+
Community discussion commonly frames NAD+ around energy, mental clarity, recovery and sleep. Reports are notably inconsistent, including people describing fatigue rather than increased energy. Evidence for NR or NMN must not be presented as direct evidence for administered NAD+.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
More usable energy through the day
Interest often starts with fatigue, an afternoon slump or feeling depleted despite enough time in bed. People want ordinary tasks to feel easier, rather than a brief stimulating sensation around an infusion.
- What makes a report informative
- Daily function and whether any perceived benefit persists.
- What can muddy the picture
- Rest, hydration and the infusion setting can contribute to how someone feels.
Clearer thinking and less brain fog
The cellular-energy story attracts people who struggle with attention, mental stamina or finding words. A meaningful experience would change work or conversation, rather than only creating a vague feeling of clarity.
- What makes a report informative
- Concentration on familiar tasks and mental stamina over time.
- What can muddy the picture
- Sleep, stress, caffeine and the cause of brain fog are major competing explanations.
Recovery and healthy-ageing interest
Some interest is preventive: maintaining vitality, recovering from busy periods and supporting long-term cellular health. This is a different proposition from treating a particular symptom.
- What makes a report informative
- Concrete changes in function rather than a general sense of rejuvenation.
- What can muddy the picture
- NAD biology and results for NR or NMN do not establish the benefits of an NAD+ infusion.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
More energy / less fatigue
Human findings & limits
Insufficient for broad wellness claim
Laboratory & animal context
Mechanistic rationale exists
What this means: A popular theory, but subjective reports conflict and precursor evidence cannot be transferred directly to NAD+.
Mental clarity / less brain fog
Human findings & limits
Insufficient
Laboratory & animal context
Mechanistic interest
What this means: Community-reported benefit; not established as a general clinical effect of NAD+ administration.
Better sleep
Human findings & limits
Insufficient
Laboratory & animal context
Not enough to establish benefit
What this means: Anecdotal signal only; some users instead report tiredness or altered energy.
Anti-aging / longevity
Human findings & limits
Not established
Laboratory & animal context
Biological rationale / animal research
What this means: Mechanism and biomarker changes should not be presented as proof of extended human healthspan or lifespan.
Research sources and further reading
Additional community discussions linked in this profile
These public discussions are anecdotal and may include unsupported claims or advice.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Direct NAD+ administration has some human research, but protocols vary substantially by indication and setting.
PUBLISHED HUMAN RESEARCH
View source ↗Real-world IV tolerability pilot ↗
Commercial-clinic clients
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Commercial-clinic clients. Route: Given into a vein (IV). The study lasted 4 consecutive days; 30-day follow-up. The figures below describe the research design, not a personal schedule.
| First amount studied | 500 mg IV per day |
|---|---|
| How often? | Daily |
| How was it given? | Given into a vein (IV) |
| How long? | 4 consecutive days; 30-day follow-up |
See the exact study wording +
Start / initial: 500 mg IV per day
End / target: 500 mg IV per day
Frequency: Daily
Route: Intravenous
Study duration: 4 consecutive days; 30-day follow-up
Source: PMID 41704678 ↗
Retrospective real-world study; not an efficacy dosing standard.
PUBLISHED HUMAN RESEARCH
View source ↗Ischemic cardiomyopathy RCT ↗
180 adults with ischemic cardiomyopathy
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved 180 adults with ischemic cardiomyopathy. Route: Given into a vein (IV). The study lasted 7 days. The figures below describe the research design, not a personal schedule.
| First amount studied | 10 mg/day |
|---|---|
| How often? | Daily |
| How was it given? | Given into a vein (IV) |
| How long? | 7 days |
See the exact study wording +
Start / initial: 10 mg/day
End / target: 10 mg/day
Frequency: Daily
Route: Intravenous
Study duration: 7 days
Source: PMID 40954388 ↗
Disease-specific research protocol; not transferable to wellness use.
PUBLISHED HUMAN RESEARCH
View source ↗NAD+ metabolome PK pilot ↗
Human cohort
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Human cohort. Route: Given into a vein (IV). The study lasted 6 hours. The figures below describe the research design, not a personal schedule.
| First amount studied | 3 micromoles per minute given slowly over time |
|---|---|
| How often? | given continuously |
| How was it given? | Given into a vein (IV) |
| How long? | 6 hours |
See the exact study wording +
Start / initial: 3 μmol/min infusion
End / target: 3 μmol/min infusion
Frequency: Continuous infusion
Route: Intravenous
Study duration: 6 hours
Source: PMID 31572171 ↗
Pharmacokinetic/metabolomic protocol.
COMMUNITY DISCUSSION
Commercial/community practice ≠ validated regimenWhat people commonly discuss
STARTING APPROACHES
Wellness clinics and online communities discuss a very wide range of IV protocols.
DURATION / CYCLES
Single infusions, short multi-day courses and periodic infusions are all discussed.
MAINTENANCE DISCUSSION
Regular 'maintenance' infusions are marketed and discussed, but a general evidence-based maintenance interval has not been established.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial injection example
Community example · not clinically validatedThis describes a community injection pattern. Intravenous NAD+ research cannot establish the amounts or tolerability of this subcutaneous example.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–1 | 50 mg |
| Weeks 2–2 | 75 mg |
| Weeks 3–8 | 100 mg |
Frequency: Every day · 1 entry per scheduled day.
This calendar copy stops after the first eight weeks of a longer editorial description. Eight weeks is a planning window, not an established course.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with NAD+
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDNAD+
→
OFTEN EXPLORED WITHNAD+ + NMN / NR
NAD+ + NMN / NR
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
Safety context
SAFETY & UNCERTAINTY
Direct IV NAD+ has a separate product-quality risk
What the current evidence saysFDA has warned that food-grade NAD+ is not suitable for sterile compounding without appropriate processing because of microbial/endotoxin contamination risk. FDA has received adverse-event reports after injectable NAD+ use consistent with excessive endotoxins.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
A January 2026 FDA warning letter described an NAD+ compounded lot with excessive bacterial endotoxins after three patients developed symptoms and were directed to emergency care.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
9 sourcesSources used on this profile
Systematic reviewNAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidencePubMed ↗Original publicationNAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidenceJournal / DOI ↗Systematic reviewEvaluation of safety and effectiveness of NAD in different clinical conditions: a systematic reviewPubMed ↗Original publicationEvaluation of safety and effectiveness of NAD in different clinical conditions: a systematic reviewJournal / DOI ↗Published dosing contextReal-world IV tolerability pilotPMID 41704678 ↗Published dosing contextIschemic cardiomyopathy RCTPMID 40954388 ↗Published dosing contextNAD+ metabolome PK pilotPMID 31572171 ↗Professional sourceSafety and uncertaintyFDA sterile-compounding reminder ↗Professional sourceSafety and uncertaintyFDA warning letter · Jan 2026 ↗
CURRENT STATUS
How to interpret its position today
Route/product dependent
NAD+ is a biological coenzyme rather than a single authorised medicine category; claims and product status depend on formulation and route.
Sterile-compounding cautions
FDA has warned about use of food-grade NAD+ for sterile compounding.
FDA ↗Route/product dependent
Regulatory status depends on the specific product, claim and route; production should resolve this at product level.
Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.